Search results for "Lebrikizumab"
showing 3 items of 3 documents
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised…
2015
Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma.We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled patients with asthma aged 12-75 years (from 128 clinical research centres in study 1 and 104 centres in study 2) from Asia, Australia, North America, South America, South Africa, and Europe, whose asthma was inadequately c…
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
2012
BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. We aimed to establish efficacy, safety, and patient characteristics associated with the response to mepolizumab. METHODS: We undertook a multicentre, double-blind, placebo-controlled trial at 81 centres in 13 countries between Nov 9, 2009, and Dec 5, 2011. Eligible patients were aged 12-74 years, had a history of recurrent severe asthma exacerbations, and had signs of eosinophil…
Atopiska dermatīta smaguma pakāpes korelācija ar laboratorisko kritēriju un biežākas blaknes pacientiem ar bioloģisko terapiju
2021
Mērķis: Izpētīt un salīdzināt visbiežākās blaknes nemolizumab un lebrikizumab medikamentiem. Izpētīt laboratorisko rādītāju korelāciju ar AD smaguma pakāpi.Uzdevumi: Noteikt korelatīvas sakarības starp EASI, IgE, eozinofīliem leikocītiem, neitrofīliem leikocītiem, LDH. Salīdzināt nemolizumab un lebrikizumab medikamentu drošību. Materiāli un metodes: Retrospektīvs pētījums attiecībā uz 1.hipotēzi, izmantojot ambulatoro pacientu kartiņas. Pacienti ar vidēji smagu, smagu AD (kopā 59 cilvēki). Randomizēti, dubultakli, placebo-kontrolēti, multicentriski pētījumi, attiecība uz 2.hipotēzi. Kopējais pacientu skaits, ieskaitot pacientus, kuri saņēma bioloģisko terapiju - 424 (lebrikizumab) un 649 (n…